The estimated Net Worth of Xinzhou Li is at least $1.24 millió dollars as of 11 December 2012. Mr. Li owns over 120,000 units of Novabay Pharmaceuticals Inc stock worth over $1,016,116 and over the last 12 years he sold NBY stock worth over $224,400. In addition, he makes $0 as Director at Novabay Pharmaceuticals Inc.
Sign up
Mr. Li NBY stock SEC Form 4 insiders trading
Xinzhou has made over 4 trades of the Novabay Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 120,000 units of NBY stock worth $224,400 on 20 September 2013.
The largest trade he's ever made was buying 1,200,000 units of Novabay Pharmaceuticals Inc stock on 31 October 2012 worth over $1,500,000. On average, Xinzhou trades about 224,000 units every 37 days since 2012. As of 11 December 2012 he still owns at least 2,120,000 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Mr. Li stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Xinzhou Li biography
Xinzhou (Paul) Li is Director of the Company. He has been the Chairman and Executive Director of China Pioneer Pharma since 2013 (also serving in the role of chief executive officer from November 2013 to December 2014), which, along with its affiliates, is the exclusive distributor of NovaBay’s NeutroPhase® Skin and Wound Cleanser in China and Southeast Asia, as well as NovaBay’s largest stockholder. Mr. Paul Li has not been appointed to any committees. Mr. Paul Li previously served as the Board’s Asia-Pacific advisor for over two (2) years. Mr. Paul Li founded China Pioneer Pharma in July 1996, and is responsible for managing its operations and planning, and for formulating the company’s strategies. He has more than nineteen (19) years of experience in the pharmaceutical services industry and has more than twenty-one (21) years of experience in international trading and management. Prior to China Pioneer Pharma, Mr. Paul Li worked at the Hainan branch of Sumitomo Corporation from 1988 to 1995. Mr. Paul Li graduated from Jianghan Petroleum Normal School with a diploma in English and studied at the China Europe International Business School. The Board believes that Mr. Paul Li’s extensive knowledge of NovaBay’s products and of the pharmaceutical industry generally, his leadership of a successful company dedicated to the promotion and marketing of imported pharmaceutical products and medical devices, and his expertise in the international area, are all skills that are important to our Board. In addition, as a representative of NovaBay’s largest stockholder, Mr. Paul Li is uniquely positioned to represent stockholder interests.
How old is Xinzhou Li?
Xinzhou Li is 54, he's been the Director of Novabay Pharmaceuticals Inc since 2015. There are 4 older and 5 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.
What's Xinzhou Li's mailing address?
Xinzhou's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.
Insiders trading at Novabay Pharmaceuticals Inc
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... és Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
What does Novabay Pharmaceuticals Inc's logo look like?
Complete history of Mr. Li stock trades at Novabay Pharmaceuticals Inc
Novabay Pharmaceuticals Inc executives and stock owners
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Justin M. Hall Esq.,
Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director -
Justin Hall,
President, Chief Executive Officer, Director -
Andrew Jones,
Chief Financial Officer, Treasurer -
Swan Sit,
Independent Director -
Yenyou Zheng,
Independent Director -
Paul Freiman,
Independent Director -
Mijia Wu,
Director -
Xinzhou Li,
Director -
Dr. Jeffrey Kunin M.D.,
Pres of DERMAdoctor -
Dr. Audrey Kunin M.D.,
Chief Product Officer -
Yongxiang Zheng,
Director -
Julie Garlikov,
Director -
Wang Xu,
NEO - Sr Mgr and Controller -
Lewis J Stuart,
Chief Commercial Officer -
Yanbin Liu,
Director -
Jason Philip Raleigh,
Interim CFO and Treasurer -
Xiaoyan Liu,
Director -
Gail J Maderis,
Director -
Todd Erik Zavodnick,
Director -
Pharma (Singapore) Pte. Ltd...,
10% owner -
T. Alex Mc Pherson,
Director -
Thomas J Paulson,
Chief Financial Officer -
Yonghao Ma,
Director -
Jian Ping Fu,
10% owner -
Massimo Radaelli,
Director -
Mark M Sieczkarek,
Director -
Pharma (Hong Kong) Co Ltd P...,
10% owner -
John Joseph Mc Govern,
Int Pres, CEO, CFO & Treasurer -
John James O'reilly,
Chief Financial Officer -
Colin Scott,
VP, Clinical Research & Dev't -
Keith R Bley,
SVP Product Development -
Pioneer Pharma Holdings Ltd...,
10% owner -
Roy J Wu,
SVP Bus & Corp Development -
David W. Stroman,
SVP, Ophthalmic Product Devt. -
Tony D.S. Wicks,
Director -
Anthony Dailley,
Director -
Robert R. Tufts,
Director -
Charles Cashion,
Director -
Behzad Khosrovi,
VP, Research & Dev't -
Ramin Najafi,
Chief Executive Officer -
Area Pioneer Pharma Co., Lt...,
10% owner -
Ramin Najafi Family Trust D...,
Chief Executive Officer -
Mark Brian Anderson,
CSO -
Harry F Jr Hixson,
Director -
Russell A. Hoon,
Senior Vice President -
Xiaopei Wang,
-
Jeffrey Kunin,
President, DERMAdoctor, LLC -
Audrey Kunin,
Chief Product Officer